What do you consider when choosing an aromatase inhibitor?

FEMARA® (letrozole): A proven record in the initial adjuvant setting and across the treatment spectrum1*

FEMARA® (letrozole) has been helping postmenopausal women with HR+ early breast cancer for more than a decade1,2

FEMARA® is an aromatase inhibitor (AI) that was first introduced in 1996 for the treatment of advanced breast cancer after the failure of anti-estrogen therapy.1,2 Since then, FEMARA® has been proven effective across multiple treatment settings for postmenopausal women with hormone-receptor–positive (HR+) breast cancer, including initial adjuvant, extended adjuvant, and first-line metastatic.1

FEMARA® (letrozole) for treatment of various breast cancer stages1,2

FEMARA® (letrozole) plays a major role in the treatment of postmenopausal women with HR+ early breast cancer

As initial adjuvant therapy

In postmenopausal patients with HR+ early breast cancer, the risk of incurable distant metastases initially peaks just 2 years after surgery.3 FEMARA® is the only AI as standard initial adjuvant therapy that significantly reduces the early risk of distant metastases.1,4†

Click here for more information.


Following adjuvant tamoxifen

Patients who have completed 5 years of adjuvant tamoxifen therapy are still at substantial risk for recurrence and mortality.5 FEMARA® provides these patients with the only approved extended adjuvant option—delivering significant reductions in overall recurrence, including distant metastases, following 5 years of tamoxifen therapy in a placebo-controlled trial.1,5-7

Click here for more information.


FEMARA® has a demonstrated safety profile

FEMARA® is generally well tolerated across all approved treatment settings.1
FEMARA® is contraindicated in cases of known hypersensitivity to the active substance or to any of the excipients, in women with premenopausal endocrine status, and during pregnancy and lactation. The most frequently reported adverse reactions in the clinical studies were hot flushes, arthralgia, nausea, and fatigue.

Click here for additional safety information.


FEMARA offers simple and convenient dosing

The recommended adult dose of FEMARA® (letrozole) is one 2.5-mg tablet once daily.1

For adjuvant therapy for your postmenopausal patients with HR+ early breast cancer, turn to FEMARA®.

To learn more about FEMARA® (letrozole), please visit the following sections:

Making a Difference
Mechanism of Action
Dosage and Administration
Summary of Product Characteristics


*Not all indications for FEMARA® are approved in all countries.
†Distant disease-free survival is a secondary end point of BIG 1-98; the primary end point of the study is disease-free survival. Approval is
 based on a median 26-month follow-up.1

FEMARA® (letrozole) is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

FEMARA® (letrozole) is also indicated for:

Extended adjuvant treatment of hormone–dependent early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.

First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.

Advanced breast cancer in women with natural or artificially induced postmenopausal status after relapse or disease progression, who have previously been treated with anti-estrogens.

Click here for Important Safety Information for FEMARA®.

References: 1. FEMARA® (letrozole) [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2009. 2. Data on file. Novartis Oncology, East Hanover, NJ. 3. Mansell J, Monypenny IJ, Skene AI, et al. Distant metastasis-the most common type of early recurrence with adjuvant tamoxifen therapy. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Texas. 4. Gradishar W. Landmark trials in endocrine adjuvant therapy for breast carcinoma. Cancer. 2006;106(5):975-981. 5. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-1271. 6. Arimidex® (anastrazole) [summary of product characteristics]. Luton, UK: AstraZeneca UK Limited; 2007. 7. Aromasin® (exemestane) [summary of product characteristics]. Sandwich, UK: Pharmacia Ltd; 2008.